Johnson & Johnson Operating Margin 2010-2024 | JNJ

Current and historical operating margin for Johnson & Johnson (JNJ) over the last 10 years. The current operating profit margin for Johnson & Johnson as of September 30, 2024 is 28.35%.
Johnson & Johnson Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2024-09-30 $87.70B $17.63B 20.10%
2024-06-30 $86.58B $19.51B 22.53%
2024-03-31 $85.65B $20.06B 23.42%
2023-12-31 $85.16B $15.06B 17.69%
2023-09-30 $76.31B $12.72B 16.67%
2023-06-30 $74.96B $12.68B 16.91%
2023-03-31 $77.46B $12.21B 15.76%
2022-12-31 $79.99B $19.36B 24.20%
2022-09-30 $77.21B $18.11B 23.46%
2022-06-30 $80.55B $16.79B 20.84%
2022-03-31 $79.85B $17.61B 22.06%
2021-12-31 $78.74B $19.18B 24.36%
2021-09-30 $91.45B $19.59B 21.42%
2021-06-30 $89.19B $20.14B 22.58%
2021-03-31 $84.21B $17.42B 20.68%
2020-12-31 $82.58B $16.50B 19.98%
2020-09-30 $80.86B $19.07B 23.58%
2020-06-30 $80.50B $16.31B 20.27%
2020-03-31 $82.73B $19.42B 23.47%
2019-12-31 $82.06B $17.33B 21.12%
2019-09-30 $81.71B $16.23B 19.87%
2019-06-30 $81.33B $19.01B 23.37%
2019-03-31 $81.59B $16.94B 20.76%
2018-12-31 $81.58B $18.00B 22.06%
2018-09-30 $81.38B $17.44B 21.43%
2018-06-30 $80.68B $17.80B 22.07%
2018-03-31 $78.69B $17.58B 22.34%
2017-12-31 $76.45B $17.67B 23.12%
2017-09-30 $74.36B $19.44B 26.14%
2017-06-30 $72.53B $19.93B 27.48%
2017-03-31 $72.17B $20.08B 27.83%
2016-12-31 $71.89B $19.80B 27.55%
2016-09-30 $71.60B $19.24B 26.87%
2016-06-30 $70.88B $18.08B 25.51%
2016-03-31 $70.18B $18.92B 26.95%
2015-12-31 $70.07B $19.20B 27.39%
2015-09-30 $70.52B $18.14B 25.73%
2015-06-30 $71.88B $20.83B 28.98%
2015-03-31 $73.59B $20.71B 28.15%
2014-12-31 $74.33B $20.56B 27.66%
2014-09-30 $74.43B $20.61B 27.69%
2014-06-30 $73.54B $17.47B 23.75%
2014-03-31 $71.92B $16.63B 23.13%
2013-12-31 $71.31B $15.47B 21.69%
2013-09-30 $70.52B $15.82B 22.44%
2013-06-30 $69.99B $15.75B 22.50%
2013-03-31 $68.59B $12.99B 18.94%
2012-12-31 $67.22B $13.78B 20.49%
2012-09-30 $65.92B $10.99B 16.68%
2012-06-30 $64.87B $11.51B 17.74%
2012-03-31 $65.00B $12.90B 19.84%
2011-12-31 $65.03B $12.36B 19.01%
2011-09-30 $64.42B $14.27B 22.15%
2011-06-30 $63.40B $14.38B 22.68%
2011-03-31 $62.13B $15.18B 24.43%
2010-12-31 $61.59B $16.95B 27.52%
2010-09-30 $62.49B $17.32B 27.72%
2010-06-30 $62.59B $17.35B 27.72%
2010-03-31 $62.50B $17.39B 27.83%
2009-12-31 $61.90B $15.76B 25.45%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $373.206B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $755.038B 78.21
Novo Nordisk (NVO) Denmark $479.268B 34.56
AbbVie (ABBV) United States $323.263B 17.02
Merck (MRK) United States $257.112B 17.08
Novartis AG (NVS) Switzerland $216.194B 14.37
AstraZeneca (AZN) United Kingdom $209.663B 17.84
Pfizer (PFE) United States $148.532B 10.16
Sanofi (SNY) $123.059B 11.15
Innoviva (INVA) United States $1.189B 9.89